<DOC>
	<DOCNO>NCT02211989</DOCNO>
	<brief_summary>To investigate safety , tolerability pharmacokinetics , pharmacodynamics BI 14332 CL</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Rising Oral Doses BI 14332 CL Powder Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male include base complete medical history , include physical examination , vital sign ( BP , HR ) , 12lead ECG , clinical laboratory test Age ≥18 Age ≤50 year Body Mass Index ( BMI ) ≥18.5 BMI ≤29.9 kg/m2 Signed date write informed consent prior admission study accordance GCP local legislation Any finding medical examination ( include BP , HR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre Any ECG value outside reference range clinical relevance include , limited QRS interval &gt; 120 m mark baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m QT &gt; 500 m ) A history additional risk factor Torsades de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) The use concomitant medication prolong QT/QTc interval</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>